Marizyme is a biotechnology business based in the US. Marizyme shares (MRZM) are listed on the PINK and all prices are listed in US Dollars. Its last market close was $0.00 – the same closing value as a week prior.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.00 |
|---|---|
| 52-week range | $0.00 - $0.10 |
| 50-day moving average | $0.02 |
| 200-day moving average | $0.03 |
| Wall St. target price | N/A |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.04 |
Historical closes compared with the close of $0.0003 from 2025-04-24
| 1 week (2025-04-18) | 0.0003 |
|---|---|
| 1 month (2025-03-27) | -96.30% |
| 3 months (2025-01-27) | -99.40% |
| 6 months (2024-10-25) | -99.50% |
| 1 year (2024-04-26) | -99.70% |
|---|---|
| 2 years (2023-04-26) | -99.77% |
| 3 years (2022-04-26) | 1.91 |
| 5 years (2020-04-24) | 2.02 |
| Revenue TTM | $183,417 |
|---|---|
| Gross profit TTM | $116,048 |
| Return on assets TTM | -26.57% |
| Return on equity TTM | -3137.71% |
| Profit margin | 0% |
| Book value | $-0.12 |
| Market Capitalization | $39,537 |
TTM: trailing 12 months
We're not expecting Marizyme to pay a dividend over the next 12 months.
You may also wish to consider:
Marizyme's shares were split on a 1:29 basis on 26 July 2018 . So if you had owned 29 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Marizyme shares – just the quantity. However, indirectly, the new 2800% higher share price could have impacted the market appetite for Marizyme shares which in turn could have impacted Marizyme's share price.
Over the last 12 months, Marizyme's shares have ranged in value from as little as $0.0003 up to $0.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Marizyme's is 0.988. This would suggest that Marizyme's shares are less volatile than average (for this exchange).
To put Marizyme's beta into context you can compare it against those of similar companies.
Marizyme, Inc. , a multi-technology biomedical company, develops and commercializes medical technologies to enhances patients health. It's product portfolio includes DuraGraft, a first-in-class, De Novo granted and CE marked intra-operative vascular graft storage and flushing solution used during coronary artery bypass graft (CABG) surgeries; MATLOC, a point-of-care, lab-on-chip technology platform, developed for quantitative chronic kidney disease assessment; and Krillase, a protein enzyme that acts to break protein bonds and has applications in wound debridement, wound healing, dental care and thrombosi. The company also engages in the development of MAR-FG-001, a fat grafting technology for the use during fat grafting procedures. Marizyme, Inc. was formerly known as GBS Enterprises Incorporated and changed its name to Marizyme, Inc. in March 2018.
Track the progress of the S&P 500 stocks to make more informed investment decisions.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Stock lending allows investors to loan out their existing stocks, although it has both advantages and disadvantages.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.